Scholar Rock (SRRK) Stock Price, News & Analysis

+0.14 (+1.12%)
(As of 11:33 AM ET)
Today's Range
50-Day Range
52-Week Range
164,728 shs
Average Volume
771,393 shs
Market Capitalization
$1.01 billion
P/E Ratio
Dividend Yield
Price Target

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating
3.17 Rating Score
101.5% Upside
$25.17 Price Target
Short Interest
16.78% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.09mentions of Scholar Rock in the last 14 days
Based on 10 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.31) to ($2.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

117th out of 914 stocks

Biological Products, Except Diagnostic Industry

14th out of 153 stocks

SRRK stock logo

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

SRRK Stock News Headlines

Scholar Rock (NASDAQ:SRRK) Stock Price Down 7.3%
Scholar Rock to Host Investor Day on May 22, 2024
SRRK Oct 2024 15.000 put
SRRK Oct 2024 20.000 call
SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp (2QK.BE)
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$33.19 million
Book Value
$2.29 per share


Free Float
Market Cap
$996.13 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Jay Thomas Backstrom M.D. (Age 69)
    M.P.H., President, CEO & Director
    Comp: $1.07M
  • Mr. Edward H. Myles MBAMr. Edward H. Myles MBA (Age 52)
    CFO, COO & Treasurer
    Comp: $720.79k
  • Ms. Tracey M. Sacco M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $548.86k
  • Mr. Mo Qatanani Ph.D. (Age 51)
    Chief Scientific Officer
  • Rushmie Nofsinger
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Junlin Ho J.D. (Age 45)
    General Counsel & Corporate Secretary
    Comp: $563.73k
  • Ms. Caryn Parlavecchio (Age 52)
    Chief Human Resources Officer
  • Ms. Lisa Amaya Price
    Senior Vice President of Human Resources
  • Ms. Erin Moore (Age 49)
    Senior Vice President of Finance
  • Mr. Ryan Iarrobino
    Senior Vice President of Clinical Development & Operations

SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price target for 2024?

6 Wall Street analysts have issued 1-year target prices for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they expect the company's share price to reach $25.17 in the next twelve months. This suggests a possible upside of 101.5% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2024?

Scholar Rock's stock was trading at $18.80 at the beginning of 2024. Since then, SRRK shares have decreased by 33.6% and is now trading at $12.49.
View the best growth stocks for 2024 here

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our SRRK earnings forecast

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.11. During the same period in the prior year, the firm earned ($0.46) earnings per share.

What ETF holds Scholar Rock's stock?

iShares Neuroscience and Healthcare ETF holds 3,905 shares of SRRK stock, representing 1.58% of its portfolio.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (10.29%), Redmile Group LLC (8.05%), Vanguard Group Inc. (3.72%), Bellevue Group AG (2.71%), Hood River Capital Management LLC (0.99%) and Kennedy Capital Management LLC (0.35%). Insiders that own company stock include Amir Nashat, Caryn Parlavecchio, Edward H Myles, Jay T Backstrom, Jeffrey S Flier, Junlin Ho, Mo Qatanani, Public Equities LP Invus and Samsara Biocapital Gp, Llc.
View institutional ownership trends

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 5/20/2024 by Staff

From Our Partners